Opaleye Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Opaleye Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-146,700	Closed	-$2.04M	–	54
2016 Q2	$2.04M	Buy	+146,700	New	+$2.16M	1.36%	28
2015 Q1	–	Sell	-80,000	Closed	-$3.08M	–	42
2014 Q4	$3.08M	Buy	+80,000	New	+$1.91M	1.56%	24

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Opaleye Management's PRTK Position: Q3 2016 in Review

Opaleye Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 146,700 shares — an estimated $2.04M sold.

Opaleye Management first reported a position in PRTK in Q4 2014 and held it in 2 quarters. The position peaked at $3.08M in Q4 2014. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

Opaleye Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Opaleye Management sold 146,700 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $2.04M.
Opaleye Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Opaleye Management's Paratek Pharmaceuticals, Inc. position peaked at $3.08M in Q4 2014.
86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.